Jun 092015

The Hygiology Post ®  has been presenting information about a company formerly called Senesco Technologies which recently merged and rebranded to Sevion Therapeutics that seems to have much potential to help many people. As a matter of disclosure : The author continues to be a current shareholder in the company.

Last month the article “Sevion Therapeutics Presents Cow Antibody Platform at PEGS 2015” (https://www.seviontherapeutics.com/sevion-therapeutics-presents-cow-antibody-platform-at-pegs-2015/; obtained on 6-9-2015) began the following way:

SAN DIEGO, CA – May 4, 2015 – Sevion Therapeutics, Inc. (‘Sevion’ or the ‘Company’)(OTCBB: SVON), a biopharmaceutical company which discovers, develops and acquires next-generation biologics for the treatment of cancer and immunological diseases, today announced that Dr. Vaughn Smider, MD, PhD, Chief Scientific Officer, gave an oral presentation on the company’s cow-derived ultralong CDR3 antibody platform and an update on SVN-001, its antibody targeting the ion channel Kv1.3 for autoimmune diseases, at the international PEGS conference in Boston, MA on May 4, 2015.  ‘The unique ultralong CDR3s of cow antibodies provide a new domain for which to target traditionally difficult and high value antigens, and we are eager to share our discoveries and progress with the protein therapeutics community at PEGS 2015’, noted Dr. Smider.  The unique structure and genetic diversity mechanisms of cows were featured on the cover of Cell in 2013, and the company has since developed discovery and commercialization strategies based on the novel cow antibody scaffold.”

The Hygiology Post ® welcomes feedback from readers as to whether the articles (individually and/or collectively) help fulfill its vision and mission.


Louis DeCola, Jr.  © 2015                                    The Hygiology Post ®